It’s one of the most volatile stories in the financial world. In August 2016, oil prices rallied from a low of $39.19 to a high of $49.36 on hopes that oil producer talks in September 2016 would curb ballooning supply. By late August, though, oil began to pull back to a low of $42.98. All…
DetailsWhat I’m about to tell you changed my financial life. It opened up endless opportunities. From attracting the attention of wealthy investors to opening up VC opportunities to being able to pass on less-than-ideal jobs, this did it all. It’s so simple I’m somewhat embarrassed to reveal it. However, if you want less risk and…
DetailsThe Cheap Investor has traded Groupon Inc. (GRPN) quite a few times. The most recent recommendations were at just $2.79 a share in the December 2015 issue, at $4.20 in the March 2016 issue, and at $3.35 in the July 2016 issue. Shares have since rallied to a high of $5.94, handing subscribers potential gains…
DetailsSo much for the Federal Reserve’s idea that the U.S. economy is prepared for a rate hike… Shortly after the U.S. announced that employers added 155,000 jobs in August 2016 (missing estimates for 181,000) the odds of a September 2016 rate hike dropped to 18% from 82%. Of those jobs, some of the biggest gains…
DetailsJohn Maynard Keynes was right. As someone who has read all five parts of The General Theory of Employment, Interest and Money, I can tell you that’s a big claim. Keynes has been portrayed as one of history’s great economic thinkers. His theories are the foundation for the modern financial system that has created so…
DetailsAfter a sell-off in the biotech sector, we found a great deal of severely undervalued names trading at extremely low prices. It’s part of the reason why we recommended Rigel Pharmaceuticals (RIGL) at just $1.95 a share in the April 2016 issue of The Cheap Investor. Shares of RIGL are now up 108% after the company…
Details“I am running a business. I am a for-profit business. I am not hiding from that.” That was Mylan CEO, Heather Bresch’s recent reaction to the EpiPen cost controversy. And as heartless as that may sound, she’s right. Mylan’s EpiPen essentially has no competition, and that’s why the company has been able to continuously raise…
DetailsWhen I moved to the Phoenix area, the first thing I noticed is that every road is in squares. Just squares. Endless squares From the city center to 20 or 30 miles in all directions the roads make nothing but squares. Near my place in Scottsdale is an S-curve that’s wildly out of place. When…
DetailsThe summer was one of the most profitable on record for us, too. In fact, since May, here are just some of the wins collected by subscribers: Bovie Medical Corporation (BVX) up 159% Rigel Pharmaceuticals (RIGL) up 29% Goldfield Corporation (GV) up 106% MeetMe Inc. (MEET) up 135% Adverum Biotechnologies (ADVM) up 37% Groupon Inc.…
DetailsThe pharmaceuticals industry is no stranger to controversy. Plagued with runaway drug prices that have drawn the ire of Americans, the industry has come under fire, most recently from Democratic presidential nominee Hillary Clinton. But it’s not just the high cost of drugs that’s upset her. It’s also the high cost of drug delivery systems.…
Details$106,848 That’s how much it cost to run a full page ad in Section C of the New York Times. A big layout for most businesses. It’s easily justified cost for a wide-release movie. It can also be absorbed in the “branding” efforts of a big companies like Samsung who spend as much as $15…
DetailsBiotech is back…it seems. The NASDAQ Biotechnology Index is up 19% in the last month. However, I’ve got to warn you, a year and a half into the correction, I’m still not buying it at all. Here’s why. The Hidden Biotech Bust In March 2015 your editor warned: The risk/reward of biotech stocks as a…
Details